Eight hallmarks framework released for artificial intelligence in medical affairs

A structured pathway establishing eight core hallmarks for governing artificial intelligence in medical affairs has been published following an advisory consultation of 12 senior professionals, as detailed in recent industry literature. The framework aims to provide rigorous operational boundaries for deploying machine learning models and automated systems within pharmaceutical and clinical communications.

Key Clinical Takeaways:

• The framework establishes eight distinct hallmarks to govern artificial intelligence applications specifically within medical affairs operations.
• Twelve senior professionals from pharmaceutical and biomedical networks contributed professional advisory input and ratings to develop the maturity assessment structure.
• The initiative addresses regulatory compliance, methodological oversight, and implementation-science integration without relying on human-participant clinical trial data.

Advisory Consultation and Governance Methodology

The development process relied on professional advisory input rather than human-participant research, according to the authors’ methodological assessment. Twelve senior professionals from industry networks participated on a voluntary and confidential basis, evaluating draft hallmarks through individual interviews, structured instruments, and written feedback. Because the project reviewed published literature and publicly available regulatory guidance rather than conducting clinical trials with patients or animal subjects, formal written informed consent was not sought or obtained.

Contributors to the framework include individuals affiliated with multiple life sciences organizations. G.B. and T.L. contributed while employed by Novocure GmbH in Switzerland. Subsequent affiliations for contributing authors span several organizations, including Helsinn Healthcare SA in Switzerland, Miltenyi Biomedicine in Germany, Eli Lilly and Company in Germany, GSK in Switzerland, Roche/Genentech in the United States, Inhibrx, Inc. in the United States, Takeda Oncology in Switzerland, and Novartis in Switzerland. The authors emphasize that the published analysis represents independent professional work and does not necessarily reflect the official positions of their corporate employers.

Generative AI Assisted the Drafting Process

The drafting process incorporated generative AI technologies, specifically Claude Sonnet 4.5 and GPT-5, to assist with literature research, reference formatting, and structural editing. The authors note that all machine-generated output underwent critical review, verification, and substantial modification. No image-generation models were utilized, and all figures and supplementary graphics were generated deterministically from code.

The resulting framework includes a maturity assessment model and implementation tools designed to guide medical affairs teams through regulatory hurdles and compliance standards.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.